A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease.

Trial Profile

A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs CERE 120 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Ceregene; Sangamo Therapeutics
  • Most Recent Events

    • 27 Oct 2016 Planned End Date changed from 1 Nov 2014 to 1 Mar 2018.
    • 21 May 2013 Data from a secondary analysis were presented at the 16th Annual Meeting of the American Society of Gene and Cellular Therapy (ASGCT), according to a Ceregene media release.
    • 19 Apr 2013 Top-line results published in a Ceregene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top